Pediatric Oncology Clinical Trial
Official title:
Get Strong to Fight Childhood Cancer: An Exercise Intervention for Children and Adolescents Undergoing Anti-Cancer Treatment
The purpose of this multicenter study is to evaluate a personalised and standardised exercise intervention for children and adolescents undergoing anti-cancer treatment.
In the randomised, controlled FORTEe trial, high evidence for an innovative, patient-centred exercise treatment shall be generated. Supervised exercise training intents to increase muscle strength and reduce muscular atrophy due to bedrest. CRF and HRQoL can be improved and in the future, these benefits may help to fight childhood cancer by increasing therapy efficiency and survival rate. Within the project, digital, innovative technologies such as augmented reality will be developed and applied to make the exercise training more effective, age-adapted and personalised. Moreover, FORTEe will stimulate translational research to provide access to paediatric exercise oncology as a new health care intervention. As a progress beyond the current state-of-the-art, FORTEe has the ambition to implement paediatric exercise oncology as an evidence-based standard in clinical care for all childhood cancer patients across the EU and beyond. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03593525 -
SPARK Symptom Screening and Feedback to Providers
|
N/A | |
Completed |
NCT03650530 -
The Family Talk Intervention in Pediatric Oncology
|
N/A | |
Completed |
NCT02612025 -
Effects of Resistance and Endurance Training in Pediatric Cancer Patients During Intensive Treatment Phase
|
N/A | |
Active, not recruiting |
NCT06445816 -
Does the Level of Pain in Pediatric Oncology Patients Affect the Level of Psychological Resilience in Parents?
|
||
Recruiting |
NCT05867186 -
Fit to Fight Childhood Cancer
|
||
Completed |
NCT05691816 -
The Experience of the Child With Cancer When Port à Cath Needle : Child's Speech
|
||
Completed |
NCT02085148 -
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
|
Phase 1 |